Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients

• Status: Completed
• Trial end date: 2008-11-01

Summary

• The primary objective of this clinical study is to demonstrate the efficacy of the fixed combination of pyronaridine artesunate granule formulation (60:20 mg; paediatric PYRAMAX®) by showing a PCR-corrected adequate clinical and parasitological cure rate of more than 90%.

• Treatment success or failures will be classified according to WHO Guidelines 2005

• Phase: Phase 3

Details

• Lead Sponsor: Medicines for Malaria Venture
• Collaborator: Shin Poong Pharmaceuticals
• Treatments: Artemether-lumefantrine combination; Artemisinins; Artesunate; Lumefantrine; Pyronaridine